Logo Image

Authors

Jeremy D. Handel, MD
Latest Article

Case review: An incidentally discovered renal mass

An expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.

Morgan Bayer
Latest Article

2-year data show continued enfortumab vedotin efficacy in cisplatin-ineligible MIBC

Updated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.

Hayley Virgil
Latest Article

Olaparib plus abiraterone/prednisone linked with improved PFS in mCRPC

The median PFS was 39 months (95% CI, 22-not reached [NR]) in arm 3 compared with 8.4 months (95% CI, 2.9-17.0) in arm 1 and 14 months (95% CI, 8.4-20.0) in arm 2.

Sabrina Serani
Latest Article

Apalutamide combo hits high 2-year RFS rate in prostate cancer

Treatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.

Allegheny Health Network
Latest Article

AHN Offering Advanced Urological Care Close to Home for Patients in Erie

The recent expansion of AHN Saint Vincent Allied Urology was purposefully designed to enhance every aspect of the patient experience.

Stephanie Gleicher, MD, MPH

Gleicher is a fellow in female pelvic medicine and reconstructive urology at Vanderbilt University Medical Center in Nashville, Tennessee.

Latest Article

The status and future direction of advanced urine testing: multiplex PCR

"Given that PCR testing may have a benefit for specific cohorts, it is recommended that more clinical evidence be provided to better guide Medicare in defining 'medical necessity,' ” write Stephanie Gleicher, MD, MPH, and Roger R. Dmochowski MD, MMHC, FACS.

Bob Kronemyer
Latest Article

Dr. Cheryl Iglesia highlights the evolving treatment paradigm for overactive bladder

“New data indicate that long-term use of some of these overactive bladder drugs is not good for cognitive function,” explains Iglesia.

Courtney Flaherty
Latest Article

Genomic and imaging advances drive precision medicine progress in prostate cancer

Rohan Garje, MD, discusses precision medicine in metastatic prostate cancer, including genomic testing, targeted therapies, and theragnostics.

Jessica Skarzynski
Latest Article

Darolutamide safety in nmCRPC sustained with prolonged exposure

Safety findings from the final analysis of the phase 3 ARAMIS trial showed that the androgen receptor inhibitor remained well tolerated with longer treatment.

Morgan Petronelli
Latest Article

Study assesses impact of health literacy on chronic pelvic pain

Addressing the gaps in health literacy may lead to improvement in health outcomes and health care disparities among patients with chronic pelvic pain.

Austin Ward
Latest Article

Automated medical coding benefits both the practice and the patients

When you add automation, your medical coding not only improves your margins but also plays a key role in improving patient care.

Lourdes Guerrios Rivera, MD, MSc
Latest Article

The UroOnc Minute: Keeping Patients Engaged in Active Surveillance, With Lourdes Guerrios-Rivera, MD, MSc

In this episode of The UroOnc Minute, Lourdes Guerrios-Rivera, MD, discusses strategies to improve patient engagement and adherence during active surveillance for prostate cancer, highlighting the critical roles of education, communication, and structured follow-up.

Denise Juhr
Latest Article

Urologic research and COVID-19: Unmasking the silver lining

In this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.

Hannah Slater
Latest Article

Treatment at high-volume facilities linked to improved survival in node-positive prostate cancer

The improved survival was observed in patients treated at high-volume radiation centers with external-beam radiation therapy plus androgen-deprivation therapy.

Jonathan Henderson, MD
Latest Article

Radioligands and ADT alternatives emerge in prostate cancer treatment

Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation.

Alan H. Bryce, MD
Latest Article

Alan Bryce, MD, highlights key phase 3 advances in prostate cancer

Alan Bryce, MD, breaks down the key prostate cancer studies that he believes are going to change practice from ASCO 2026.

Francesca A. Williamson, PhD
Latest Article

Is video-based research feasible for pediatric urology visits?

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.

Bryn Launer, MD

Launer is a urology resident at Vanderbilt University Medical Center, Nashville, Tennessee.

Latest Article

Considerations for palliative care in urologic oncology

Benefits include improved quality of life and symptom management.

United Urology Group
Latest Article

United Urology Group and its affiliate practices and Prostate Centers USA® are collaborating to revolutionize men's health care with minimally invasive solutions

The inclusion of PAE in the American Urological Association BPH Guidelines offers a non-surgical alternative that can provide long-term relief with minimal downtime and fewer complications, according to the United Urology Group.

Colleen Moretti
Latest Article

Triplet therapy including darolutamide should be standard of care in mCSPC, data indicate

Results of the ARASENS trial (NCT02799602) demonstrated that darolutamide plus ADT and docetaxel prolonged overall survival regardless of disease volume or risk.

Tracy Ann Politowicz
Latest Article

FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC

The agency issued a PDUFA target action date of June 14, 2027.

Brielle Benyon
Latest Article

Real-world data point to underutilization of germline, somatic testing in mCRPC

"Certainly germline and somatic is recommended for all mCRPC patients to detect HR gene mutations, and consider options for PARP inhibitors,” says Neal Shore, MD, FACS.

Parviz K. Kavoussi, MD
Latest Article

Chronic orchialgia: How to diagnose and treat the challenging condition

In this interview, Parviz K. Kavoussi, MD, discusses his diagnostic work-up for patients who present with chronic testicular pain and describes conservative and surgical management approaches for the condition.

Terri Gatchel-Schmidt
Latest Article

Expert explains why automation is key to prior authorization reform

Automating prior authorization is an investment that every health care organization should consider. As the industry grapples with rapid regulatory shifts and acute staff shortages, a tailored automation strategy is key to enhancing patient care and improving operational efficiency.

Chelsea King Arthur
Latest Article

How data and technology facilitate health equity and boost the overall patient experience

"Digital engagement technology, which can be seamlessly integrated into a health system or hospital's existing processes," writes Chelsea King Arthur.

Brian Hudson
Latest Article

Is a medical scribe right for your practice?

“Regardless of the size of the practice, medical scribes are a valuable resource for health care providers, helping to streamline workflow and coordinate patient care,” writes Brian Hudson.

Glenn T. Werneburg, MD, PhD
Latest Article

Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidance

Urinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.

Kristi Rosa
Latest Article

Combo of cabozantinib and pembrolizumab shows promise in frontline urothelial carcinoma

Results from the phase 2 PemCab trial showed that the first-line combination elicited promising antitumor activity with tolerable toxicity in patients with advanced urothelial carcinoma, including those who were cisplatin ineligible.

Gina Mauro
Latest Article

FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC

The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.

Jax DiEugenio
Latest Article

Expert highlights program addressing disparities in prostate cancer care

In this interview, Mary-Ellen Taplin, MD, discusses disparities in prostate cancer care and a unique initiative aiming to alleviate those disparities.